1. Home
  2. MDGL vs TX Comparison

MDGL vs TX Comparison

Compare MDGL & TX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • TX
  • Stock Information
  • Founded
  • MDGL 2011
  • TX 1961
  • Country
  • MDGL United States
  • TX Luxembourg
  • Employees
  • MDGL N/A
  • TX N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • TX Steel/Iron Ore
  • Sector
  • MDGL Health Care
  • TX Industrials
  • Exchange
  • MDGL Nasdaq
  • TX Nasdaq
  • Market Cap
  • MDGL 7.4B
  • TX 6.7B
  • IPO Year
  • MDGL N/A
  • TX 2006
  • Fundamental
  • Price
  • MDGL $325.99
  • TX $33.58
  • Analyst Decision
  • MDGL Buy
  • TX Strong Buy
  • Analyst Count
  • MDGL 14
  • TX 3
  • Target Price
  • MDGL $347.33
  • TX $52.33
  • AVG Volume (30 Days)
  • MDGL 654.8K
  • TX 154.5K
  • Earning Date
  • MDGL 10-31-2024
  • TX 11-05-2024
  • Dividend Yield
  • MDGL N/A
  • TX 9.79%
  • EPS Growth
  • MDGL N/A
  • TX N/A
  • EPS
  • MDGL N/A
  • TX 0.40
  • Revenue
  • MDGL $76,813,000.00
  • TX $18,703,544,000.00
  • Revenue This Year
  • MDGL N/A
  • TX $7.13
  • Revenue Next Year
  • MDGL $193.46
  • TX $2.98
  • P/E Ratio
  • MDGL N/A
  • TX $82.83
  • Revenue Growth
  • MDGL N/A
  • TX 15.27
  • 52 Week Low
  • MDGL $168.25
  • TX $30.68
  • 52 Week High
  • MDGL $368.29
  • TX $44.44
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 62.52
  • TX 39.78
  • Support Level
  • MDGL $272.72
  • TX $33.21
  • Resistance Level
  • MDGL $323.99
  • TX $34.47
  • Average True Range (ATR)
  • MDGL 19.26
  • TX 1.05
  • MACD
  • MDGL -2.73
  • TX -0.15
  • Stochastic Oscillator
  • MDGL 48.41
  • TX 2.13

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

About TX Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)

Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel, Usiminas and Mining. In its steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The Usiminas segment include iron ore extraction, steel transformation, production of capital goods and logistics. The vast majority of its revenue comes from the steel segment and geographically from Mexico.

Share on Social Networks: